Parkinson’s disease
Research activity is centred on Parkinson’s disease, with a particular focus on motor symptom progression and clinical outcomes measured through established neurological rating scales.
- Motor progression
- Movement disorder assessment
- Clinical symptom evaluation
The sponsor’s trials are aligned with the study of functional impairment in Parkinson’s disease and the monitoring of changes in daily living and motor performance.
GBA1-associated Parkinson’s disease
One major area of interest is GBA1-related Parkinson’s disease, reflecting attention to genetically defined patient groups and disease mechanisms linked to pathogenic variants.
- Genetic Parkinson’s disease
- GBA1 mutation carriers
- Inherited neurodegenerative disease
This focus places emphasis on targeted neurological research in a molecularly characterised form of Parkinson’s disease.
Neurology and movement disorders
The sponsor’s clinical research is positioned within neurology, especially the treatment and assessment of movement disorders affecting motor control and disease burden.
- Neurological therapeutics
- Motor function
- Disorder progression
Trial activity spans multiple collaborating sites across several countries, supporting research in specialised neurological care settings.
Renal impairment and pharmacokinetics
Additional clinical interest extends to renal impairment, with attention to how kidney function influences pharmacokinetics, safety, and tolerability in treated participants.
- Kidney function
- Drug disposition
- Safety evaluation
This area supports the clinical characterisation of treatment use in populations with varying degrees of renal dysfunction.
